馃敟 驴Qu茅 ensayos est谩n marcando la conversaci贸n en #ESMO26?
Junto a @OncoAlert analizamos en tiempo real con ACUVOX la respuesta de la oncolog铆a m茅dica:
馃煝 Warmly received: DeLLphi-305 (+84), VOLGA (+74), HEALER (+100) y NATALEE (+61).
馃敶 Coolly received: KEYNOTE-866 (-61) y TALENT (-61).
鈿栵笍 Most divisive: ET-FES (50% split) y NIAGARA (42% split).
Sigue la conversaci贸n en vivo:
馃憠 https://f.mtr.cool/k9a907cymt
#ESMO26 #ACUVOX #OncoAlert #OncoBites
22 views 路 3 likes 路 2 reposts 路 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgSustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgPerioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905
https://esmocongress.esmo.orgSource: Oncobites.tv 路 x.com